 |
1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate |
|---|---|
| Trade Name | |
| Orphan Indication | Hormone refractory prostate carcinoma |
| USA Market Approval | USA |
| USA Designation Date | 2000-01-18 00:00:00 |
| Sponsor | Cell Therapeutics, Inc.;201 Elliott Avenue West, Suite 400;Seattle, Washington, 98119 |
